New Braasch Biotech Vaccine Technology Provides Growth Hormone and IGF - Market Wire
CHICAGO, IL–(Marketwire - August 31, 2009) - Braasch Biotech LLC announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome
Cytokinetics Presents Phase IIa Clinical Trials Data Relating to - PR Inside
SOUTH SAN FRANCISCO, CA — (Marketwire) — 08/31/09 — Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients
Regulatory questions for Astra, Boehringer drugs - Forbes
BARCELONA, Aug 31 (Reuters) - AstraZeneca and Boehringer Ingelheim both unveiled strong results for new heart drugs at the European Society of Cardiology congress at the weekend — but neither is guaranteed a home run with regulators. Experts said
Rat Poison Alternative Cuts Clots, May Change Therapy (Update1) - Bloomberg
Aug. 31 (Bloomberg) — Millions of heart patients worldwide may benefit from a breakthrough blood thinner that is likely to replace warfarin, a rat poison doctors crafted into a potent and unwieldy medicine half a century ago, cardiologists said
Moss Rehabilitation Research Institute Launches Largest Study to Date - PR Inside
Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore
New Cancer Drug Delivery System Is Effective and Reversible - PhysOrg
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any potentially dangerous side effects. Investigators
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw - Biloxi Sun Herald
NEW YORK, Aug. 31 /PRNewswire-FirstCall/ — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present an overview of the Company’s lead drug candidates, KRX-0401 (perifosine
ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to - Biloxi Sun Herald
MADISON, Conn., Aug 31 /PRNewswire/ — The results of the initial clinical trial of the ClariVein(TM) catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Wednesday, September 2, at the XVIth World Meeting of
New Braasch Biotech Vaccine Technology Provides Growth Hormone and IGF - Market Wire
CHICAGO, IL–(Marketwire - August 31, 2009) - Braasch Biotech LLC announces its lead vaccine for Obesity, Growth Hormone Deficiencies may have beneficial use for numerous IGF-1 responsive disorders such as diabetes, heart disease and Rett Syndrome
Cytokinetics Presents Phase IIa Clinical Trials Data Relating to - PR Inside
SOUTH SAN FRANCISCO, CA — (Marketwire) — 08/31/09 — Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients
Regulatory questions for Astra, Boehringer drugs - Forbes
BARCELONA, Aug 31 (Reuters) - AstraZeneca and Boehringer Ingelheim both unveiled strong results for new heart drugs at the European Society of Cardiology congress at the weekend — but neither is guaranteed a home run with regulators. Experts said
Rat Poison Alternative Cuts Clots, May Change Therapy (Update1) - Bloomberg
Aug. 31 (Bloomberg) — Millions of heart patients worldwide may benefit from a breakthrough blood thinner that is likely to replace warfarin, a rat poison doctors crafted into a potent and unwieldy medicine half a century ago, cardiologists said
Moss Rehabilitation Research Institute Launches Largest Study to Date - PR Inside
Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore
New Cancer Drug Delivery System Is Effective and Reversible - PhysOrg
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug also must spare healthy cells, and ideally its effects will be reversible to cut short any potentially dangerous side effects. Investigators
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw - Biloxi Sun Herald
NEW YORK, Aug. 31 /PRNewswire-FirstCall/ — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present an overview of the Company’s lead drug candidates, KRX-0401 (perifosine
ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to - Biloxi Sun Herald
MADISON, Conn., Aug 31 /PRNewswire/ — The results of the initial clinical trial of the ClariVein(TM) catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Wednesday, September 2, at the XVIth World Meeting of
